Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired (Tables)

Licenses Acquired (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of research and development-licenses

As such, for the three and six months ended June 30, 2019 and 2018, the purchase price of licenses acquired was classified as research and development-licenses acquired in the Condensed Consolidated Statements of Operations as reflected in the table below:


	Three Months Ended June 30,				Six Months Ended June 30,
($ in thousands)	2019		2018		2019		2018
Fortress Companies:
Helocyte	$	—	$	—	$	—	$	21
Mustang		200		—		650		75
Aevitas		—		1		—		1
Cellvation		—		—		—		1
Total	$	200	$	1	$	650	$	98

Schedule of research and development for licenses acquired

For the three and six months ended June 30, 2019 and 2018, Mustang recorded the following expense in research and development for licenses acquired:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
($in thousands)	2019		2018		2019		2018
City of Hope (COH) – CD123 (MB-102)	$	—	$	—	$	250	$	—
Nationwide Children’s Hospital – C134 (MB‑108)		—		—		200		—
CSI City of Hope Milestone (MB-104)		200				200
Manufacturing License		—		—		—		75
Total licenses acquired expense	$	200	$	—	$	650	$	75